Stocks · Healthcare · Biotechnology
CytomX Therapeutics, Inc. CTMX
$2.56 -2.66% Close, Oct 2, 2026 · NASDAQ · Market cap $557.3M
Weak trendHigh risk
Next earnings report: Nov 5, 2026
Scroll or pinch to zoom, drag to move. Daily prices adjusted for splits. Markers: E = earnings (green beat, red miss), S = split, D = dividend.
Three things to know
- Diluted EPS over the last four quarters was $-0.45, down 178.1% year over year.
- Revenue over the last four quarters was $18.3M, down 87.0% from a year earlier, slowing from -75.9% a quarter earlier.
- Operating margin narrowed to -476.2% from 30.6% a year earlier.
PromtFinance scores
Each score is a percentile within the Healthcare sector (0–100). Under each score: how the stock ranks in its sector on every component. As of Oct 5, 2026.
How fast revenue, earnings and cash flow are growing.
- Revenue growth (TTM, YoY)Bottom 6%
- EPS growth (TTM, YoY)Bottom 12%
- Revenue growth, 3-year CAGRTop 44%
- Revenue growth accelerationBottom 16%
Returns on capital, margins, earnings quality and balance-sheet strength.
- Return on invested capitalBottom 46%
- Gross marginTop 8%
- Operating marginBottom 17%
- Accruals (lower is better)Bottom 15%
How cheap the shares are relative to earnings, cash flow and their own history.
- Earnings yieldBottom 36%
- Free-cash-flow yieldBottom 30%
- EBITDA / enterprise valueBottom 32%
- Sales / enterprise valueBottom 17%
Strength and persistence of the price trend, including versus the S&P 500.
- 12-month return excluding last monthBottom 42%
- 6-month returnBottom 7%
- 1-year return vs S&P 500Bottom 27%
- Distance from 52-week highBottom 9%
- Trend checklist (0–4)Bottom 14%
Earnings surprises and analyst sentiment (estimate-revision history is being collected).
- Average EPS surprise, last 4 quartersBottom 12%
- Consecutive EPS beatsBottom 20%
- Share of analysts rating BuyTop 43%
- Upside to consensus price targetTop 16%
Low volatility, shallow drawdowns, low market sensitivity and modest leverage.
- Volatility, 60 days (lower is better)Bottom 40%
- Maximum drawdown, 3 yearsBottom 12%
- Beta vs S&P 500 (lower is better)Bottom 2%
What changed
Latest four quarters versus the same period a year earlier (growth: versus one quarter earlier).
| Measure | Before | Now | |
|---|---|---|---|
| Revenue growth (YoY) | -75.9% | -87.0% | ↓ |
| EPS growth (YoY) | -172.2% | -178.1% | ↓ |
| Gross margin | 100.0% | 98.6% | ↓ |
| Operating margin | 30.6% | -476.2% | ↓ |
| FCF margin | -55.1% | -450.7% | ↓ |
Fundamental momentum
| Measure | Now (TTM) | Year / quarter before | Sector rank | |
|---|---|---|---|---|
| Revenue growth (TTM, YoY) | -87.0% | -75.9% | ↓ | Bottom 6% |
| EPS growth (TTM, YoY) | -178.1% | -172.2% | ↓ | Bottom 12% |
| Gross margin | 98.6% | 100.0% | ↓ | Top 8% |
| Operating margin | -476.2% | 30.6% | ↓ | Bottom 17% |
| Net margin | -435.2% | 34.0% | ↓ | — |
| Free-cash-flow margin | -450.7% | -55.1% | ↓ | — |
| Return on invested capital | -25.4% | — | Bottom 46% | |
| Revenue growth, 3-year CAGR | 12.8% | — | Top 44% |
Quality of earnings and balance sheet
- Accruals (net income − OCF) / assetsLower is better; high accruals can signal weaker earnings quality.
- 0.7%
- Stock-based compensation / revenueA cost to shareholders through dilution.
- 55.4%
- Receivables growth vs revenue growthReceivables growing much faster than sales can be a warning.
- +1993.1 pp
- Net debt / EBITDABelow 1× is conservative; above 3× is high leverage.
- Net cash
Shareholder returns
- Dividend yield (dividends paid, TTM)
- 0.00%
- Net buyback yield (TTM)
- -45.20%
- Shareholder yield
- -45.20%
- Share count change, 1 year
- +69.6%
- Share count change, 3-year CAGR
- +48.7%
Shareholder yield = dividends + net buybacks over the last four quarters, divided by market cap.
Based on the four quarters through Jun 30, 2026 (filed Aug 6, 2026).
Earnings and expectations
Earnings momentum
- Consecutive EPS beats
- 0
- Beats in the last 8 reports
- 5 of 8
- Average EPS surprise, last 4
- -61.4%
- Average 2-day reaction, last 8
- +21.0%
- Positive 20 days after report
- 3 of 8
Analysts
- Consensus price target
- $8.50
- Target vs current price
- +232.0%
- Analysts with a rating
- 21
- Share rating Buy or Strong Buy
- 81%
- Consensus rating
- Buy
How the stock reacted to recent reports
| Report date | EPS surprise | 2 days | 5 days | 20 days | 60 days |
|---|---|---|---|---|---|
| Aug 6, 2026 | -16.8% | +0.6% | +4.2% | +11.0% | — |
| May 7, 2026 | +28.6% | -3.1% | -8.2% | -23.0% | -23.2% |
| Mar 16, 2026 | -175.0% | +44.2% | -4.9% | -6.2% | -36.3% |
| Nov 6, 2025 | -82.5% | -0.5% | +0.5% | -3.1% | +44.2% |
| Aug 7, 2025 | +98.1% | -3.2% | -18.0% | -3.2% | +53.5% |
| May 12, 2025 | +116.3% | +129.4% | +118.7% | +184.4% | +133.7% |
| Mar 6, 2025 | +195.7% | +0.3% | -2.7% | -1.1% | +330.8% |
| Nov 7, 2024 | +141.2% | +0.0% | +1.0% | +16.0% | -6.2% |
Returns from the close before each report. Past reactions do not determine future ones.
Earnings history
| Report date | EPS | Estimate | Surprise | Revenue |
|---|---|---|---|---|
| Aug 6, 2026 | -$0.09 | -$0.08 | -16.8% | $1.4M |
| May 7, 2026 | -$0.10 | -$0.14 | +28.6% | $10.3M |
| Mar 16, 2026 | -$0.22 | -$0.08 | -175.0% | $661,000 |
| Nov 6, 2025 | -$0.09 | -$0.05 | -82.5% | $6.0M |
| Aug 7, 2025 | -$0.00 | -$0.06 | +98.1% | $18.7M |
| May 12, 2025 | $0.27 | $0.12 | +116.3% | $50.9M |
| Mar 6, 2025 | $0.22 | -$0.23 | +195.7% | $38.1M |
| Nov 7, 2024 | $0.07 | -$0.17 | +141.2% | $33.4M |
Valuation in context
| Multiple | Now | 5-year median | 5-year percentile | Sector rank (cheapness) |
|---|---|---|---|---|
| EV / Sales | 29.82× | — | — | Bottom 17% |
| Free-cash-flow yield | -14.80% | — | — | Bottom 30% |
| Earnings yield | -17.58% | — | — | Bottom 36% |
P/E over the past five years
Range 1.5× – 136.4× since Dec 31, 2023. Each point: price on the filing date divided by trailing-twelve-month EPS known then.
What moved the stock over the past year
- Price return, 1 year
- -23.6%
- Earnings per share growth (TTM)
- -178.1%
- Change in P/E multiple
- +72.7%
Most of the move came from a change in the valuation multiple.
Technical state
Trend checklist
- ✗ Price above 20-day average
- ✗ Price above 50-day average
- ✗ Price above 200-day average
- ✗ 50-day average above 200-day
- ✗ MACD histogram positive
Trend quality
- Days above the 50-day average
- 0
- Days above the 200-day average
- 0
- 50-day average slope (20 days)
- -7.9%
- 200-day average slope (20 days)
- -2.4%
- Distance from 50-day average
- -20.0%
- Distance from 200-day average
- -36.9%
- RSI (14)
- 32.1
- Relative volume
- 0.65×
Risk and drawdowns
- Volatility, 60 days (annualized)
- 60.8%
- Volatility vs own 5-year history
- 31th percentile · Normal for this stock
- Beta vs S&P 500 (2 years, weekly)
- 2.94
- Correlation with S&P 500
- 0.39
- Current drawdown from 1-year high
- -62.1%
- Maximum drawdown, 3 years
- -91.6%
Largest declines in the past six years
| From peak | To low | Decline | Length | Recovery |
|---|---|---|---|---|
| Apr 28, 2021 | Apr 7, 2025 | -95.7% | 990 days | Not yet recovered |
| Feb 12, 2021 | Apr 12, 2021 | -25.1% | 39 days | 9 days (Apr 23, 2021) |
| Jan 19, 2021 | Jan 21, 2021 | -22.2% | 2 days | 12 days (Feb 8, 2021) |
| Dec 14, 2020 | Dec 31, 2020 | -17.1% | 12 days | 10 days (Jan 15, 2021) |
Declines of 10% or more from a closing high, measured on daily closes.
Financial statements
- Market cap
- $557.3M
- EPS, diluted (TTM)
- -$0.45
- Revenue (TTM)
- $18.3M
- 52-week range
- $2.55 – $8.21
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $37.3M | $53.2M | $101.2M | $138.1M | $76.2M |
| Gross profit | $37.3M | $53.2M | $101.2M | $138.1M | $76.2M |
| Operating income | -$116.0M | -$101.3M | -$6.5M | $25.0M | -$22.4M |
| Net income | -$115.9M | -$99.3M | -$569,000 | $31.9M | -$17.4M |
| EPS (diluted) | -$1.26 | -$1.48 | -$0.01 | $0.38 | -$0.15 |
| Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $33.4M | $38.1M | $50.9M | $18.7M | $6.0M | $663,000 | $10.3M | $1.4M |
| Net income | $5.7M | $18.9M | $23.5M | -$154,000 | -$14.2M | -$26.5M | -$18.2M | -$20.7M |
| EPS (diluted) | $0.07 | $0.24 | $0.27 | -$0.00 | -$0.09 | -$0.17 | -$0.10 | -$0.09 |
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Operating cash flow | -$119.0M | -$110.8M | -$56.0M | -$86.2M | -$75.6M |
| Capital expenditure | -$1.6M | -$1.7M | -$840,000 | -$310,000 | -$220,000 |
| Free cash flow | -$120.6M | -$112.5M | -$56.9M | -$86.5M | -$75.8M |
| Dividends paid | $0 | $0 | $0 | $0 | $0 |
| Net share buybacks | $107.7M | $648,000 | $30.2M | $6.9M | $110.4M |
Cash outflows are shown as negative numbers.
- Cash and short-term investments
- $330.3M
- Total assets
- $381.2M
- Total liabilities
- $79.2M
- Total debt
- $5.7M
- Net debt
- -$11.5M
- Shareholders’ equity
- $302.1M
As of Jun 30, 2026 (filed Aug 6, 2026).
Short interest
- Shares sold short
- 38,639,220
- Days to cover
- 9.29
- Change vs previous report
- +15.3%
FINRA short interest, settlement date Sep 15, 2026.